Delayed diagnosis in X-linked agammaglobulinemia and its relationship to the occurrence of mutations in BTK non-kinase domains

ABSTRACT Background: X-linked agammaglobulinemia (XLA) is characterized by the absence of immunoglobulin and B cells. Patients suffer from recurrent bacterial infections from early childhood, and require lifelong immunoglobulin replacement therapy. Mutations in BTK (Bruton’s Tyrosine Kinase) are associated with this phenotype. Some patients that present XLA do not show typical clinical symptoms, resulting in delayed diagnosis due to the lack of a severe phenotype. This study presents a report of five XLA patients from four different families and attempts to determine a relationship between delayed diagnosis and the occurrence of BTK mutations. Methods: Samples from patients with antibody deficiency were analyzed to determine BTK expression, immunophenotyping and mutation analysis. Clinical and laboratory data was analyzed and presented for each patient. Results: Most patients presented here showed atypical clinical and laboratory data for XLA, including normal IgM, IgG, or IgA levels. Most patients expressed detectable BTK protein. Sequencing of BTK showed that these patients harbored missense mutations in the pleckstrin homology and Src-homology-2 domains. When it was compared to public databases, BTK sequencing exhibited a new change, along with three other previously reported changes. Conclusions: Delayed diagnosis and atypical manifestations in XLA might be related to mutation type and BTK expression.

[1]  A. Rawat,et al.  A child with X-linked agammaglobulinemia and Kawasaki disease: an unusual association , 2017, Rheumatology International.

[2]  L. Santos‐Argumedo,et al.  Variations of B cell subpopulations in peripheral blood of healthy Mexican population according to age: Relevance for diagnosis of primary immunodeficiencies. , 2016, Allergologia et immunopathologia.

[3]  Yi-dan Zhang,et al.  Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia , 2016, Medicine.

[4]  L. Santos‐Argumedo,et al.  Clinical and mutational features of X-linked agammaglobulinemia in Mexico. , 2016, Clinical immunology.

[5]  O. Ohara,et al.  Mutations in Bruton’s tyrosine kinase impair IgA responses , 2015, International Journal of Hematology.

[6]  J. B. Oliveira,et al.  ICON: The Early Diagnosis of Congenital Immunodeficiencies , 2014, Journal of Clinical Immunology.

[7]  Marta Tormos-Pérez,et al.  Structural and functional in silico analysis of LRRK2 missense substitutions , 2014, Molecular Biology Reports.

[8]  L. Santos‐Argumedo,et al.  Brutonˈs tyrosine kinase—an integral protein of B cell development that also has an essential role in the innate immune system , 2014, Journal of leukocyte biology.

[9]  H. Ochs,et al.  Coding-region alterations in BTK do not universally cause X-linked agammaglobulinemia. , 2013, The Journal of allergy and clinical immunology.

[10]  H. Chen,et al.  Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient , 2013, BMC Pediatrics.

[11]  S. Sutçuoglu,et al.  X-Linked Agammaglobulinemia Presenting with Secondary Hemophagocytic Syndrome: A Case Report , 2013, Case reports in medicine.

[12]  I. Adzhubei,et al.  Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.

[13]  Y. Lau,et al.  Tyrosine Kinase Btk Is Required for NK Cell Activation , 2012, The Journal of Biological Chemistry.

[14]  S. Pourjabbar,et al.  Autoimmunity in X-linked agammaglobulinemia: Kawasaki disease and review of the literature , 2012, Expert review of clinical immunology.

[15]  H. Kanegane,et al.  Atypical case of X‐linked agammaglobulinemia diagnosed at 45 years of age , 2011, Pediatrics international : official journal of the Japan Pediatric Society.

[16]  K. Warnatz,et al.  Importance of B cell co‐stimulation in CD4+ T cell differentiation: X‐linked agammaglobulinaemia, a human model , 2011, Clinical and experimental immunology.

[17]  M. Conley Genetics of hypogammaglobulinemia: what do we really know? , 2009, Current opinion in immunology.

[18]  Mauno Vihinen,et al.  Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain , 2009, Immunological reviews.

[19]  M. Chiriacò,et al.  Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells: XLA diagnosis or not? , 2008, Clinical immunology.

[20]  E. Kasasbeh,et al.  X-linked agammaglobulinemia diagnosed late in life: case report and review of the literature , 2008, Clinical and molecular allergy : CMA.

[21]  L. Santos‐Argumedo,et al.  Characterization of Bruton's tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia. , 2008, Molecular immunology.

[22]  E. López-Granados,et al.  Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X‐linked agammaglobulinaemia cellular model , 2008, Clinical and experimental immunology.

[23]  H. Kanegane,et al.  X-Linked Agammaglobulinemia Diagnosed in Adulthood: A Case Report , 2006, International journal of hematology.

[24]  E. López-Granados,et al.  A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia. , 2005, The Journal of allergy and clinical immunology.

[25]  Jessica M. Lindvall,et al.  Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling , 2005, Immunological reviews.

[26]  S. Weston,et al.  Identification of the bruton tyrosine kinase (BTK) gene mutations in 20 Australian families with X‐linked agammaglobulinemia (XLA) , 2004, Human mutation.

[27]  D. Gillis,et al.  Phenotypic variability: clinical presentation between the 6th year and the 60th year in a family with X-linked agammaglobulinemia. , 2004, The Journal of allergy and clinical immunology.

[28]  R. Gelman,et al.  Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. , 2003, The Journal of allergy and clinical immunology.

[29]  J. V. van Dongen,et al.  XLA Patients with BTK Splice-Site Mutations Produce Low Levels of Wild-Type BTK Transcripts , 2002, Journal of Clinical Immunology.

[30]  H. Kanegane,et al.  Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X‐linked agammaglobulinemia , 2002, Human mutation.

[31]  H. Kanegane,et al.  Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. , 2001, The Journal of allergy and clinical immunology.

[32]  D. Nelson,et al.  The clinical spectrum of bruton’s agammaglobulinemia , 2001, Current allergy and asthma reports.

[33]  H. Ochs,et al.  Bruton's tyrosine kinase is a substrate of calpain in human platelets , 2001, FEBS letters.

[34]  D. Nelson,et al.  A case of X-linked agammaglobulinemia diagnosed in adulthood. , 2001, Clinical immunology.

[35]  I. Caragol,et al.  Kinase mutant Btk results in atypical X‐linked agammaglobulinaemia phenotype , 2000, Clinical and experimental immunology.

[36]  D. Olive,et al.  Tec kinases: a family with multiple roles in immunity. , 2000, Immunity.

[37]  H. Kanegane,et al.  Atypical X-linked agammaglobulinemia diagnosed in three adults. , 1999, Internal medicine.

[38]  P. Janmey,et al.  Pleckstrin Homology Domains Interact with Filamentous Actin* , 1999, The Journal of Biological Chemistry.

[39]  K. Mikoshiba,et al.  Mutation of the Pleckstrin Homology Domain of Bruton's Tyrosine Kinase in Immunodeficiency Impaired Inositol 1,3,4,5-Tetrakisphosphate Binding Capacity* , 1996, The Journal of Biological Chemistry.

[40]  G. Litman,et al.  A Novel Mutation (Cys145→Stop) in Bruton’s Tyrosine Kinase Is Associated with Newly Diagnosed X-Linked Agammaglobulinemia in a 51-Year-Old Male , 1996, Molecular medicine.

[41]  T. Kunikata,et al.  Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan. , 1996, Blood.

[42]  R. Thompson,et al.  X linked agammaglobulinaemia with a 'leaky' phenotype. , 1996, Archives of disease in childhood.

[43]  O. Witte,et al.  Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. , 1994, The New England journal of medicine.

[44]  J. V. van Dongen,et al.  The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages , 1993, European journal of immunology.

[45]  D J Rawlings,et al.  Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. , 1993, Science.

[46]  Ornella Parolini,et al.  Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia , 1993, Cell.

[47]  I. Kondratenko,et al.  Recent thymic emigrants, T regulatory cells, and BAFF level in children with X-linked agammaglobulinaemia in association with chronic respiratory disease. , 2018, Allergologia et immunopathologia.

[48]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[49]  S. Rosenzweig,et al.  Clinical and Molecular Analysis of 49 Patients With X-linked Agammaglobulinemia From A Single Center in Argentina , 2008, Journal of Clinical Immunology.

[50]  C. Roifman,et al.  Newly diagnosed X-linked agammaglobulinemia (XLA), bruton's tyrosine kinase (Btk) mutation, in a 39 year-old male , 2002 .

[51]  Benfang Lei,et al.  Stability and peptide binding specificity of Btk SH2 domain: Molecular basis for X‐linked agammaglobulinemia , 2000, Protein science : a publication of the Protein Society.

[52]  D. Vetrie,et al.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases , 1993, Nature.

[53]  M. Conley,et al.  Molecular approaches to analysis of X-linked immunodeficiencies. , 1992, Annual review of immunology.